Kyverna Therapeutics, Inc Common Stock

Yahoo Finance • 22 hours ago

KYVERNA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation Into Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) on beha... Full story

Yahoo Finance • 9 days ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved expanded disability status scale scores (EDSS) KYV-101 continues to demonstrate a tolerable sa... Full story

Yahoo Finance • 18 days ago

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up​ Enrollment for registrational Phase 3 portion of KYSA-6 trial in MG on track to initiate by year-end 2025 EMERYVILLE, Calif.,... Full story

Yahoo Finance • last month

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

KYV-101 has the potential to deliver durable, drug-free, disease-free remission in myasthenia gravis and set a new treatment standard for stiff person syndrome Innovative FDA-aligned KYSA-6 Phase 3 trial design for myasthenia gravis suppo... Full story

Yahoo Finance • last month

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that... Full story

Yahoo Finance • 2 months ago

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) and BLA submission anticipated in 1H 2026 Registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) to include ~60 patients with enrollment to in... Full story

Yahoo Finance • 3 months ago

KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) on behalf of long-term stoc... Full story

Yahoo Finance • 3 months ago

Kyverna Therapeutics appoints Marc Grasso as CFO

* Kyverna Therapeutics (NASDAQ:KYTX [https://seekingalpha.com/symbol/KYTX]) announced on Monday the appointment of Marc Grasso as its chief financial officer (CFO), effective today. * Most recently, Grasso served as CFO of Alector, a... Full story

Yahoo Finance • 3 months ago

Kyverna therapeutics appoints Marc Grasso as new chief financial officer

EMERYVILLE, Calif. - Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases, announced today the appointment of Marc Grasso, M.D., as its new Chief Financial O... Full story

Yahoo Finance • 6 months ago

Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR) - Grabar Law Office Is Investigating Claims on Your Behalf

PHILADELPHIA, April 17, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ: KYTX): Grabar Law Office is investigating claims on behalf of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) shareholders. The investigation concerns wheth... Full story

Yahoo Finance • 6 months ago

Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf

PHILADELPHIA, March 24, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ: AKRO): Grabar Law Office is investigating whether certain officers and directors of Akero breached their fiduciary duties owed to the company. If you ha... Full story

Yahoo Finance • 6 months ago

Notice to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Rocket Lab USA, Inc. (NASDAQ: RKLB): Grabar Law Office is Investigating Claims on Your Behalf

PHILADELPHIA, March 21, 2025 (GLOBE NEWSWIRE) -- Driven Brands Holdings, Inc. (NASDAQ: DRVN) Class Action Survives Motion to Dismiss: A securities fraud class action complaint against Driven Brands Holdings, Inc. (NASDAQ: DRVN) has sur... Full story

Yahoo Finance • 7 months ago

Notice to Long-Term Shareholders of Archer-Daniels-Midland Co. (NYSE: ADM); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Kyverna Therapeutics, Inc. (Nasdaq: KYTX); and Mercury Systems, Inc. (Nasdaq: MRCY): Grabar Law Office is Investigating Claims on Your Behalf

PHILADELPHIA, March 18, 2025 (GLOBE NEWSWIRE) -- Archer-Daniels-Midland Company (NYSE: ADM) Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of shareholders of Archer-Daniels-Midland Company... Full story

Yahoo Finance • 7 months ago

Notice to Long-Term Shareholders of Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Is Investigating Claims on Your Behalf

PHILADELPHIA, March 17, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (NASDAQ: FLNC): Grabar Law Office is investigating claims on behalf of Fluence Energy, Inc. (NASDAQ: FLNC) shareholders. The investigation concerns whether certain o... Full story

Yahoo Finance • 7 months ago

Long-Term Shareholder Notice: Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf

PHILADELPHIA, March 13, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (NASDAQ: FLNC): Grabar Law Office is investigating claims on behalf of Fluence Energy, Inc. (NASDAQ: FLNC) shareholders. The investigation concerns whether certain o... Full story

Yahoo Finance • 8 months ago

Investors in Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX

NEW YORK, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Kyverna Therapeutics, Inc. ("Kyverna Therapeutics, Inc." or the "Company") (NASDAQ: KYTX) of a class action securities lawsuit. CLASS DEFINITION: Th... Full story

Yahoo Finance • 8 months ago

Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX). Shareholders who purchased shares of KYTX during the class period listed are encour... Full story

Yahoo Finance • 8 months ago

DEADLINE ALERT for KYTX, SUI, MGPI, APLT Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

BENSALEM, Pa., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the d... Full story

Yahoo Finance • 8 months ago

KYTX DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important February 7 Deadline in Securities Class Action – KYTX

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to Kyverna’s initial public of... Full story

Yahoo Finance • 8 months ago

Kyverna Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. February 7, 2025 Deadline to file Lead Plaintiff Motion.

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 04, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NASDAQ: KYTX)... Full story